Every open market buy and sale of Tarsus Pharmaceuticals, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $20.8M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when TARS insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an TARS officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every TARS insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Bobak R. AzamianPresident/CEO and Board Chair | Sale plan | 10,000 | $80.31 | $803K | 817,991 | Nov 17Form 4 |
| Sep 15, 2026 | William J Link PhdDirector | Sale plan | 12,500 | $78.38 | $980K | 94,487 | Sep 17Form 4 |
| Sep 4, 2026 | Seshadri NeervannanCOO | Sale plan | 4,564 | $85.00 | $388K | 78,532 | Sep 9Form 4 |
| Sep 4, 2026 | Bobak R. AzamianPresident/CEO and Board Chair | Sale plan | 10,000 | $90.56 | $906K | 827,991 | Sep 9Form 4 |
| Sep 4, 2026 | Elizabeth Yeu LinChief Medical Officer | Sale plan | 13,953 | $87.50 | $1.2M | 1,590 | Sep 9Form 4 |
| Sep 2, 2026 | Bobak R. AzamianPresident/CEO and Board Chair | Sale plan | 10,000 | $80.06 | $801K | 837,991 | Sep 3Form 4 |
| Sep 2, 2026 | Elizabeth Yeu LinChief Medical Officer | Sale plan | 11,578 | $77.56 | $898K | 4,770 | Sep 3Form 4 |
| Jun 17, 2026 | Bobak R. AzamianPresident/CEO and Board Chair | Sale plan | 10,000 | $61.55 | $615K | 847,991 | Jun 22Form 4 |
| Jun 16, 2026 | Jeffrey S FarrowSee Remarks | Sale | 14,396 | $60.95 | $877K | 56,801 | Jun 17Form 4 |
| Jun 15, 2026 | William J Link PhdDirector | Sale plan | 12,500 | $62.12 | $776K | 106,786 | Jun 17Form 4 |
| Jun 15, 2026 | Katherine GoodrichDirector | Sale plan | 2,954 | $62.08 | $183K | 2,233 | Jun 17Form 4 |
| Mar 20, 2026 | Seshadri NeervannanCOO | Sale plan | 2,989 | $66.75 | $200K | 82,791 | Mar 24Form 4 |
| Mar 19, 2026 | Jeffrey S FarrowSee Remarks | Sale | 6,430 | $68.36 | $440K | 43,316 | Mar 19Form 4 |
| Mar 19, 2026 | Aziz MottiwalaChief Commercial Officer | Sale | 13,056 | $68.36 | $893K | 61,480 | Mar 19Form 4 |
| Mar 19, 2026 | Seshadri NeervannanCOO | Sale | 11,324 | $68.21 | $772K | 85,780 | Mar 19Form 4 |
TARS insider trading FAQ
Are TARS insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of TARS on the open market in 0 trades, and 9 sold $20.8M in 26 trades, 65% of that under pre-arranged trading plans.
When did an TARS insider last buy shares?
There has been no open market insider purchase of TARS in the last two years.
When did an TARS insider last sell shares?
Bobak R. Azamian (President/CEO and Board Chair) sold 10,000 shares for $803K on Nov 13, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
